Kabvie 20 Tablet contains Vonoprazan 20 mg, a novel potassium-competitive acid blocker (P-CAB) indicated for the treatment of acid-related gastrointestinal disorders. Vonoprazan acts by selectively and reversibly inhibiting the H+/K+-ATPase enzyme in gastric parietal cells, leading to potent and sustained suppression of gastric acid secretion. This mechanism provides rapid onset of action and prolonged acid control compared to traditional proton pump inhibitors (PPIs). Kabvie 20 is primarily prescribed for the management of gastroesophageal reflux disease (GERD), including erosive esophagitis, and for the eradication of Helicobacter pylori infection when used in combination with appropriate antibiotics. It is also beneficial in the treatment of gastric ulcers and prevention of ulcer recurrence associated with nonsteroidal anti-inflammatory drug (NSAID) therapy. The recommended dosage is one tablet daily, taken orally, preferably before meals, with adjustments based on clinical response and patient tolerance. Kabvie 20 is generally well tolerated; common adverse effects may include headache, diarrhea, and abdominal discomfort. Caution is advised in patients with hepatic impairment, and potential drug interactions should be considered. Regular monitoring and adherence to prescribed therapy optimize therapeutic outcomes and minimize risks.

Dosage & How to Use

Dosage information not available. Please consult your doctor or pharmacist.